Antitumour necrosis factor-α therapy modulates angiopoietin-2 serum levels in non-diabetic ankylosing spondylitis patients

Annals of the Rheumatic Diseases

Volumn 72, Issue 7, 2013, Pages 1265-1267

  Genre, Fernanda ^a   Miranda Filloy, José A ^b   López Mejias, Raquel ^a   Carnero López, Beatriz ^c   Ochoa, Rodrigo ^a   Rueda, Javier ^a   González Juanatey, Carlos ^b   Blanco, Ricardo ^a   Llorca, Javier ^d   González Gay, Miguel A ^a  

^a Epidemiology Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases   (Spain)

^b HOSPITAL XERAL CALDE   (Spain)

^c HOSPITAL EL BIERZO   (Spain)

^d UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ANGIOPOIETIN 2; INFLIXIMAB;

ANKYLOSING SPONDYLITIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EFFECT; HUMAN; INFLAMMATORY DISEASE; LETTER; METABOLIC SYNDROME X; OBESITY; ONSET AGE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTEMIC DISEASE;

ANKYLOSING SPONDYLITIS; ANTI-TNF; ATHEROSCLEROSIS; INFLAMMATION;

ANGIOPOIETIN-2; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BIOLOGICAL MARKERS; COHORT STUDIES; HUMANS; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84878380147     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-203169     Document Type: Letter

References (10)

1. Azevedo VF, Pecoits-Filho R. Atherosclerosis and endothelial dysfunction in patients with ankylosing spondylitis. Rheumatol Int 2010;30:1411-16.
2. Capkin E, Kiris A, Karkucak M, et al. Investigation of effects of different treatment modalities on structural and functional vessel wall properties in patients with ankylosing spondylitis. Joint Bone Spine 2011;78:378-82.
3. Peters MJ, Visman I, Nielen MM, et al. Ankylosing spondylitis: a risk factor for myocardial infarction? Ann Rheum Dis 2010;69:579-81.
4. Heldmann F, Brandt J, van der Horst-Bruinsma IE, et al. The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol 2011;29:672-80.
5. Miranda-Filloy JA, Llorca J, Carnero-López B, et al. TNF-α antagonist therapy improves insulin sensitivity in non-diabetic ankylosing spondylitis patients. Clin Exp Rheumatol 2012;30:850-5.
6. Westra J, de Groot L, Plaxton SL, et al. Angiopoietin-2 is highly correlated with inflammation and disease activity in recent-onset rheumatoid arthritis and could be predictive for cardiovascular disease. Rheumatology (Oxford) 2011;50:665-73.
7. Fearon U, Griosios K, Fraser A, et al. Angiopoietins, growth factors, and vascular morphology in early arthritis. J Rheumatol 2003;30:260-8. (Pubitemid 36152587)
8. Krausz S, Garcia S, Ambarus CA, et al. Angiopoietin-2 promotes inflammatory activation of human macrophages and is essential for murine experimental arthritis. Ann Rheum Dis 2012;71:1402-10.
9. Pousa ID, Mate J, Salcedo-Mora X, et al. Role of vascular endothelial growth factor and angiopoietin systems in serum of Crohn's disease patients. Inflamm bowel dis 2008;14:61-7. (Pubitemid 351196870)
10. Greenberg JD, Kremer JM, Curtis JR, et al.; CORRONA Investigators. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:576-82.